SpringWorks Therapeutics
Presença
SpringWorks Therapeutics é uma das ...
SpringWorks Therapeutics é uma empresa listada sob o símbolo SWTX (US).
Executivos
Veja o organograma con seus 20 executivos principais
Biografias mais buscadas da SpringWorks Therapeutics
- Saqib Islam, Chief Executive Officer and Director
- Freda Lewis-Hall, Director
- Julie Hambleton, Director
Recentes movimentos de executivos em SpringWorks Therapeutics
- Tai-An Lin, ingressou na Companhia como Chief Scientific Officer (Notícia publicada em 12 de setembro de 2023).
Criar um alerta
para seguir os movimentos de executivos da SpringWorks Therapeutics.
Farmacêutica
SpringWorks Therapeutics possui 1.861 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacêutica
- MedMen has filed for bankruptcy protection (publicado em 28 de abril de 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado em 23 de março de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado em 19 de março de 2024).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de SpringWorks Therapeutics
- SpringWorks Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights | SpringWorks Therapeutics
- SpringWorks Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Conference | SpringWorks Therapeutics
- SpringWorks Therapeutics Appoints Carlos Albán to its Board of Directors | SpringWorks Therapeutics
- SpringWorks Therapeutics to Present Progress Across the Company’s Targeted Oncology Portfolio at Virtual R&D Day | SpringWorks Therapeutics
- SpringWorks Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference | SpringWorks Therapeutics
- SpringWorks Therapeutics Highlights Nirogacestat Clinical Data at the 2022 ASCO Annual Meeting | SpringWorks Therapeutics
- SpringWorks Therapeutics Announces Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase 3 DeFi Trial in Adult Patients with Progressing Desmoid Tumors | SpringWorks Therapeutics
- SpringWorks Therapeutics to Host Virtual R&D Day on June 10, 2022 | SpringWorks Therapeutics
- SpringWorks Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | SpringWorks Therapeutics
- SpringWorks Therapeutics Announces Pricing of Public Offering of Common Stock | SpringWorks Therapeutics
- View more press releases Close
Redes sociais sobre SpringWorks Therapeutics
- SpringWorks Therapeutics na Wikipedia, Google News e Yahoo Finance
- SpringWorks Therapeutics na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Saqib Islam 
Ligue para a SpringWorks Therapeutics em +1 917...
